ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
ImaginAb has agreed to sell its next-generation therapeutic candidates, proprietary biologics technology platform, and protein engineering facility to Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL). Post-transaction, ImaginAb will focus on developing its CD8 ImmunoPET imaging candidate, currently in Phase 2 clinical trials and licensed by multiple pharmaceutical companies for immunotherapy imaging trials. The company will also continue developing its Phase 2 prostate cancer imaging agent.
The transaction validates ImaginAb's minibody platform technology, which will enable Telix to explore new disease areas with radiotherapeutic technology. The CD8 platform development will continue, with multiple pharmaceutical companies already incorporating the technology in their immuno-oncology clinical trials. Jefferies and Stifel, Nicolaus & Company served as financial advisors for the transaction.
ImaginAb ha concordato di vendere i suoi candidati terapeutici di nuova generazione, la piattaforma tecnologica di biologici proprietari e la struttura di ingegneria proteica a Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL). Dopo la transazione, ImaginAb si concentrerà sullo sviluppo del suo candidato per l'imaging CD8 ImmunoPET, attualmente in fase 2 di studi clinici e con licenza a diverse compagnie farmaceutiche per studi di imaging in immunoterapia. L'azienda continuerà inoltre a sviluppare il suo agente di imaging per il cancro alla prostata in fase 2.
La transazione convalida la tecnologia della piattaforma minibody di ImaginAb, che consentirà a Telix di esplorare nuove aree patologiche con la tecnologia radioterapeutica. Lo sviluppo della piattaforma CD8 continuerà, con diverse compagnie farmaceutiche che stanno già incorporando la tecnologia nei loro studi clinici di immuno-oncologia. Jefferies e Stifel, Nicolaus & Company hanno prestato consulenza finanziaria per la transazione.
ImaginAb ha acordado vender sus candidatos terapéuticos de próxima generación, su plataforma tecnológica de biológicos propios y su instalación de ingeniería de proteínas a Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL). Tras la transacción, ImaginAb se centrará en desarrollar su candidato de imágenes CD8 ImmunoPET, que actualmente se encuentra en ensayos clínicos de fase 2 y cuenta con licencia de varias compañías farmacéuticas para ensayos de imágenes en inmunoterapia. La compañía también continuará desarrollando su agente de imágenes para el cáncer de próstata en fase 2.
La transacción valida la tecnología de la plataforma minibody de ImaginAb, que permitirá a Telix explorar nuevas áreas de enfermedad con tecnología radioterapéutica. El desarrollo de la plataforma CD8 continuará, con varias compañías farmacéuticas ya incorporando la tecnología en sus ensayos clínicos de inmuno-oncología. Jefferies y Stifel, Nicolaus & Company actuaron como asesores financieros para la transacción.
ImaginAb는 차세대 치료 후보 물질, 고유 생물학 기술 플랫폼 및 단백질 엔지니어링 시설을 Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL)에게 판매하기로 합의했습니다. 거래 후, ImaginAb는 현재 2상 임상 시험 중인 CD8 ImmunoPET 이미징 후보 물질 개발에 집중할 예정이며, 여러 제약사와 면역 요법 이미징 시험을 위해 라이선스 계약을 체결했습니다. 회사는 또한 2상 전립선암 이미징 제제 개발을 계속 진행할 것입니다.
이번 거래는 ImaginAb의 미니 바디 플랫폼 기술을 검증하며, Telix가 방사선 치료 기술로 새로운 질병 영역을 탐색할 수 있도록 합니다. CD8 플랫폼 개발은 계속되며, 여러 제약 회사들이 이미 이 기술을 면역 종양학 임상 시험에 포함하고 있습니다. Jefferies와 Stifel, Nicolaus & Company는 거래에 대한 재정 자문을 제공했습니다.
ImaginAb a accepté de vendre ses candidats thérapeutiques de prochaine génération, sa plateforme technologique de biologiques propriétaires et son installation d'ingénierie des protéines à Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL). Après la transaction, ImaginAb se concentrera sur le développement de son candidat à l'imagerie CD8 ImmunoPET, actuellement en essais cliniques de phase 2 et licencié par plusieurs sociétés pharmaceutiques pour des essais d'imagerie en immunothérapie. La société continuera également à développer son agent d'imagerie du cancer de la prostate en phase 2.
La transaction valide la technologie de la plateforme minibody d'ImaginAb, ce qui permettra à Telix d'explorer de nouveaux domaines de maladie avec une technologie radiothérapeutique. Le développement de la plateforme CD8 se poursuivra, avec plusieurs sociétés pharmaceutiques qui intègrent déjà la technologie dans leurs essais cliniques d'immuno-oncologie. Jefferies et Stifel, Nicolaus & Company ont agi en tant que conseillers financiers pour la transaction.
ImaginAb hat zugestimmt, seine next-generation therapeutischen Kandidaten, die proprietäre Biologika-Technologieplattform und die Protein-Engineering-Anlage an Telix Pharmaceuticals (ASX: TLX; Nasdaq: TXL) zu verkaufen. Nach der Transaktion wird sich ImaginAb auf die Entwicklung seines CD8 ImmunoPET Bildgebungssofkandidaten konzentrieren, der sich derzeit in klinischen Studien der Phase 2 befindet und von mehreren Pharmaunternehmen für Immuntherapie-Bildgebungsstudien lizenziert ist. Das Unternehmen wird auch weiterhin sein Bildgebungsagent für Prostatakrebs in Phase 2 entwickeln.
Die Transaktion bestätigt die Technologie der Minikörperplattform von ImaginAb, die es Telix ermöglichen wird, neue Krankheitsbereiche mit radiotherapeutischer Technologie zu erkunden. Die Entwicklung der CD8-Plattform wird fortgesetzt, wobei bereits mehrere Pharmaunternehmen die Technologie in ihren immunonkologischen klinischen Studien integrieren. Jefferies und Stifel, Nicolaus & Company fungierten als Finanzberater für die Transaktion.
- Strategic sale of therapeutic pipeline and technology platform to established pharmaceutical company
- Continued development and existing licenses of CD8 ImmunoPET imaging candidate in Phase 2 trials
- Multiple pharmaceutical partnerships already using the technology in clinical trials
- Retained development rights for Phase 2 prostate cancer imaging agent
- Divestment of key technology platform and research facility may limit future growth opportunities
Insights
The acquisition of ImaginAb's biologics platform marks a strategic expansion for Telix Pharmaceuticals in the rapidly growing radiopharmaceutical sector. The deal encompasses three valuable assets: a novel biologics technology platform, a pipeline of next-generation therapeutic candidates and a protein engineering facility.
The radiopharmaceutical market is experiencing substantial growth, driven by increasing demand for targeted cancer therapies. By acquiring ImaginAb's platform, Telix gains immediate access to advanced protein engineering capabilities and a ready-to-develop pipeline, potentially accelerating their development timeline for new therapeutic products. Think of this as acquiring both the recipe book (technology platform) and the professional kitchen (research facility) to create new medical treatments.
For ImaginAb, this transaction represents a strategic refocus on their imaging technology business, particularly their CD8 ImmunoPET platform, which has gained significant traction with pharmaceutical companies for immunotherapy trials. This specialization could lead to faster development and commercialization of their imaging products.
The deal's structure allows both companies to optimize their resources: Telix expands its therapeutic capabilities while ImaginAb concentrates on its imaging expertise. This type of focused strategy often leads to better execution and increased likelihood of success in the highly competitive biotech sector.
While financial terms weren't disclosed, the acquisition of a complete technology platform and research facility suggests a substantial investment by Telix. The involvement of prestigious financial advisors (Jefferies and Stifel) indicates the deal's significance and complexity.
The acquisition centers on ImaginAb's innovative minibody platform, a sophisticated technology that represents a significant advancement in targeted radiopharmaceutical development. Minibodies are engineered proteins that combine the targeting precision of antibodies with optimized properties for therapeutic applications - imagine them as smart missiles that can precisely deliver therapeutic payloads to disease sites.
This technology acquisition is particularly valuable because it provides Telix with a versatile platform for developing multiple therapeutic candidates. The protein engineering facility included in the deal gives Telix the capability to design and optimize new therapeutic agents in-house, potentially reducing development timelines and costs.
The platform's validation through ImaginAb's successful development of imaging agents suggests strong potential for therapeutic applications. The technology has already demonstrated its ability to effectively target specific biological markers, as evidenced by the CD8 ImmunoPET imaging agent's success in clinical trials.
For the broader radiopharmaceutical field, this deal represents a significant development. The combination of ImaginAb's innovative platform with Telix's existing expertise could accelerate the development of next-generation targeted radiotherapeutics, potentially leading to more effective cancer treatments.
Following the closing of this transaction, ImaginAb Inc., will focus on developing its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within immunotherapy clinical trials, primarily in oncology. In addition, ImaginAb will continue to partner in advancing the pivotal prostate cancer imaging agent, which is currently being evaluated in Phase 2 clinical trials and as a surgical resection tool.
Dr. Anna Wu, Founder of ImaginAb, commented, "We are very pleased that Telix recognizes the potential of our novel biological technology platform including enabling Telix to explore new disease areas with state-of-the-art radiotherapeutic technology. These radiopharmaceutical agents represent the culmination of significant effort and resources by our scientific team. I extend my congratulations to everyone at ImaginAb for reaching this significant milestone. This transaction further validates our novel minibody platform."
Dr. Wu continued, "With the sale of our radiopharmaceutical platform, ImaginAb will continue the development of its CD8 platform. We are encouraged that numerous pharmaceutical and biotech companies have incorporated our technology in their immuno-oncology clinical trials."
Jefferies LLC and Stifel, Nicolaus & Company, Incorporated served as financial advisors to ImaginAb on the transaction.
About ImaginAb, Inc.
ImaginAb, Inc. is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies that maintain the specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available positron emission tomography (PET) and optical imaging technology, these novel targeting agents are able to bind specifically to cell surface targets.
The company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb's pipeline and technology, visit www.imaginab.com.
About CD8 ImmunoPET
The 89Zr CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8+ cells in patients. CD8+ cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8+ cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.
About Optical PSMA
The Optical PSMA Imaging Agent (IR-800 IAB2 Minibody) is a fluorescent labelled minibody that binds the PSMA receptor present on cancer cells including prostate cancer and is used for quantitative, non-invasive PET imaging of PSMA+ cells in patients undergoing surgery to remove cancerous tissue . As such, imaging of PSMA + cells may be used to guide clinicians during surgery to identify cancerous tissue and aid tissue resection.
View original content to download multimedia:https://www.prnewswire.com/news-releases/imaginab-inc-innovative-biologics-technology-platform-acquired-by-telix-to-enable-next-generation-therapeutic-assets-discovery-302357691.html
SOURCE ImaginAb, Inc.
FAQ
What assets did Telix (TLX) acquire from ImaginAb in January 2024?
What products will ImaginAb retain after the Telix (TLX) acquisition?
How many clinical trials is ImaginAb's CD8 ImmunoPET technology currently involved in?
What is the current development stage of ImaginAb's prostate cancer imaging agent?
